Compounded tirzepatide from a verified 503B facility carries minimal additional risk compared to branded product
(AI rendering of fatty liver above) Enter GLP-1 medications Unless youve been living under a rock, you probably know that the new class of drugs called GLP-1 agonists have shown impressive results in clinical trials for diabetes, weight-loss, and even cardiovascular disease and mortality
Changes in enzyme activity, including glutathione S-transferase (GST), catalase, lipid peroxidation, and protein carbonyls, are biomarkers indicating oxidative damage in multiple aquatic organisms such as Chironomus riparius (Muiz-Gonzlez, 2021), Danio rerio (Falfushynska et al., 2022), and Dreissena polymorpha (Gonzalez-Rey and Bebianno, 2012)
Results can feel sustainable
Nutritional Challenges for GLP-1 Users While effective for weight loss, GLP-1 medications often result in decreased appetite, leading to suboptimal nutrient intake